321 related articles for article (PubMed ID: 25786900)
1. Small intestinal fungal overgrowth.
Erdogan A; Rao SS
Curr Gastroenterol Rep; 2015 Apr; 17(4):16. PubMed ID: 25786900
[TBL] [Abstract][Full Text] [Related]
2. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth.
Jacobs C; Coss Adame E; Attaluri A; Valestin J; Rao SS
Aliment Pharmacol Ther; 2013 Jun; 37(11):1103-11. PubMed ID: 23574267
[TBL] [Abstract][Full Text] [Related]
3. Does colectomy predispose to small intestinal bacterial (SIBO) and fungal overgrowth (SIFO)?
Rao SSC; Tan G; Abdulla H; Yu S; Larion S; Leelasinjaroen P
Clin Transl Gastroenterol; 2018 Apr; 9(4):146. PubMed ID: 29691369
[TBL] [Abstract][Full Text] [Related]
4. [Fungal infections of the gastrointestinal tract].
Maragkoudakis E; Realdi G; Dore MP
Recenti Prog Med; 2005 Jun; 96(6):311-7. PubMed ID: 16078762
[TBL] [Abstract][Full Text] [Related]
5. Patients with chronic renal failure have abnormal small intestinal motility and a high prevalence of small intestinal bacterial overgrowth.
Strid H; Simrén M; Stotzer PO; Ringström G; Abrahamsson H; Björnsson ES
Digestion; 2003; 67(3):129-37. PubMed ID: 12853724
[TBL] [Abstract][Full Text] [Related]
6. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome.
Pimentel M; Chow EJ; Lin HC
Am J Gastroenterol; 2000 Dec; 95(12):3503-6. PubMed ID: 11151884
[TBL] [Abstract][Full Text] [Related]
7. [Fungi in the intestine. Clinical significance].
Kreisel W
Praxis (Bern 1994); 1999 Jan; 88(1-2):5-10. PubMed ID: 10067100
[No Abstract] [Full Text] [Related]
8. Fungal infections of the gastrointestinal tract in the immunocompromised host: an update.
Lamps LW; Lai KK; Milner DA
Adv Anat Pathol; 2014 Jul; 21(4):217-27. PubMed ID: 24911247
[TBL] [Abstract][Full Text] [Related]
9. Early diagnosis of fungal infection in immunocompromised patients.
Barnes RA
J Antimicrob Chemother; 2008 Jan; 61 Suppl 1():i3-6. PubMed ID: 18063601
[TBL] [Abstract][Full Text] [Related]
10. Management of immunocompromised patients with evidence of an invasive mycosis.
Walsh TJ
Hematol Oncol Clin North Am; 1993 Oct; 7(5):1003-26. PubMed ID: 8226563
[TBL] [Abstract][Full Text] [Related]
11. Letter: coeliac disease and small intestinal bacterial overgrowth--is dysmotility the missing link?
Mooney PD; Evans KE; Sanders DS
Aliment Pharmacol Ther; 2014 Apr; 39(8):902-3. PubMed ID: 24635318
[No Abstract] [Full Text] [Related]
12. Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth.
Majewski M; Reddymasu SC; Sostarich S; Foran P; McCallum RW
Am J Med Sci; 2007 May; 333(5):266-70. PubMed ID: 17505166
[TBL] [Abstract][Full Text] [Related]
13. Current drug therapy of systemic mycoses: a review.
Yonga G
East Afr Med J; 1995 Jun; 72(6):394-8. PubMed ID: 7498014
[TBL] [Abstract][Full Text] [Related]
14. The impact of the host on fungal infections.
Perfect JR
Am J Med; 2012 Jan; 125(1 Suppl):S39-51. PubMed ID: 22196208
[TBL] [Abstract][Full Text] [Related]
15. Small Intestinal Transit Time Is Delayed in Small Intestinal Bacterial Overgrowth.
Roland BC; Ciarleglio MM; Clarke JO; Semler JR; Tomakin E; Mullin GE; Pasricha PJ
J Clin Gastroenterol; 2015 Aug; 49(7):571-6. PubMed ID: 25319735
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of small intestinal bacterial overgrowth in celiac patients with persistence of gastrointestinal symptoms after gluten withdrawal.
Tursi A; Brandimarte G; Giorgetti G
Am J Gastroenterol; 2003 Apr; 98(4):839-43. PubMed ID: 12738465
[TBL] [Abstract][Full Text] [Related]
17. Predisposing factors for positive D-Xylose breath test for evaluation of small intestinal bacterial overgrowth: a retrospective study of 932 patients.
Schatz RA; Zhang Q; Lodhia N; Shuster J; Toskes PP; Moshiree B
World J Gastroenterol; 2015 Apr; 21(15):4574-82. PubMed ID: 25914466
[TBL] [Abstract][Full Text] [Related]
18. Small intestinal bacterial overgrowth in the symptomatic elderly.
Riordan SM; McIver CJ; Wakefield D; Bolin TD; Duncombe VM; Thomas MC
Am J Gastroenterol; 1997 Jan; 92(1):47-51. PubMed ID: 8995936
[TBL] [Abstract][Full Text] [Related]
19. Triggers for driving treatment of at-risk patients with invasive fungal disease.
Drgona L; Colita A; Klimko N; Rahav G; Ozcan MA; Donnelly JP
J Antimicrob Chemother; 2013 Nov; 68 Suppl 3():iii17-iii24. PubMed ID: 24155142
[TBL] [Abstract][Full Text] [Related]
20. Current therapeutic approaches to fungal infections in immunocompromised hematological patients.
Pagano L; Caira M; Valentini CG; Posteraro B; Fianchi L
Blood Rev; 2010 Mar; 24(2):51-61. PubMed ID: 20056300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
